An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs SC-005 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 14 Dec 2018 Status changed from recruiting to discontinued.
- 28 Feb 2018 Planned End Date changed from 27 Oct 2021 to 23 Dec 2021.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.